Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Gemphire's cholesterol med gemcabene successful in mid-stage study but treatment effect less than previous trial; shares down 36% premarket

Published 08/07/2017, 08:37 AM
© Reuters. Gemphire's cholesterol med gemcabene successful in mid-stage study but treatment effect less than previous trial; shares down 36% premarket
  • Thinly traded Gemphire Therapeutics (NASDAQ:GEMP) craters 36% premarket. albeit on light volume, in response to its announcement of positive preliminary results from a Phase 2b clinical trial, ROYAL-1, assessing the ability of once-daily oral gemcabene for lowering low-density lipoprotein cholesterol (LDL-C) in patients not adequately controlled with statins and/or ezetimibe (Merck (NYSE:MRK)'s Zetia).
  • Patients receiving 600 mg of gemcabene experienced an average reduction in LDL-C of 17.2% compared to 5.5% for placebo (p=0.0057), achieving the primary endpoint.
  • Investors appear concerned, however, that the treatment effect, while positive, was less than COBALT-1, reported in June. In this study, patients receiving the same 600 mg dose experienced a mean LDL-C reduction of 30% (p=0.047).
  • Previously: Gemphire's gemcabene successful in mid-stage HoFH study; shares up 10% after hours (June 28)
  • Now read: Gemphire - Update To Thesis: The Runup Continues


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.